Comparative Effectiveness of Carotid Artery Revascularization vs Medical Therapy
Comparative Effectiveness of Carotid Artery Revascularization vs Medical Therapy
批准号:
8666037
负责人:
Salomeh Keyhani
金额:
$73.33万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-06-01 至 2015-12-31
关键词:
AddressAgeAtrial FibrillationBlood PressureCarotid ArteriesCarotid EndarterectomyCarotid StenosisCessation of lifeClinicalClinical TrialsCohort StudiesCommunitiesDataDevelopmentDiabetes MellitusDiagnosisDiseaseEarly InterventionEffectiveness of InterventionsEnrollmentHyperlipidemiaIntentionInterventionMedicalMedicareMyocardial InfarctionOperative Surgical ProceduresOutcomePatientsPerioperativeProceduresPublishingRandomized Controlled TrialsRegimenReportingRiskStrokeStroke preventionSubgroupSurgical complicationTechniquesTherapeutic InterventionTimeTransient Ischemic AttackVascular DiseasesVeteransarmbasecohortcomparative effectivenesscompare effectivenessdesignhealth administrationhuman old age (65+)hypertension controlimprovedprimary outcomepublic health relevancerisk benefit ratiotreatment strategyvascular risk factor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Randomized controlled trials (RCTs) have established that carotid endarterectomy (CEA) is superior to medical therapy in preventing stroke in both asymptomatic and symptomatic patients with carotid stenosis. However, while the majority of patients who undergo carotid revascularization receive treatment for asymptomatic disease, the benefit of revascularization for patients with asymptomatic disease is quite modest. In addition, the clinical trials were initiated about 20 years ago, and in the intervening period, medical therapy has greatly improved for this vascular disease due to new pharmacological advances such as high potency statins, improved antiplatelet regimens, and better control of hypertension, hyperlipidemia and diabetes. In parallel, as the surgical complication rate for CEA has decreased, the use of carotid artery stenting (CAS) has been gaining favor in the treatment of asymptomatic carotid stenosis. While recent trials have focused exclusively on comparing CEA to CAS, the declining stroke rate associated with medically managed carotid stenosis has led many to question whether either revascularization procedure is superior to aggressive vascular risk factor control. A three-arm RCT could answer this question, but such a study would be very expensive, not provide answers for a long time, and might only enroll the subset of healthiest patients typically studied in an RCT. Since the first RCT was published that demonstrated the superiority of CEA compared to medical therapy there has been a concern that the modest benefit observed in the trials may not be reproducible in the community. To address the ongoing debate of whether among patients with asymptomatic carotid stenosis, CEA is still superior to medical therapy and whether CAS is superior to medical therapy (which has never been evaluated in an RCT), we propose to examine the comparative effectiveness of initial medical therapy compared to early carotid intervention in a retrospective cohort study of 6000 patients using merged Veteran's Health Administration and Medicare data. We will specifically compare each revascularization strategy to medical therapy and also examine the impact of a number of key variables (e.g. age, presence of atrial fibrillation) on the comparative effectiveness of intervention compared to medical therapy. We will use advanced statistical techniques to overcome observed and unobserved differences in the medical therapy and intervention cohorts. We will compare the 30-day and 5 year outcomes of 3175 patients managed medically, 1500 patients who received CEA, and 1325 patients who received CAS entering the cohort from 2005 to 2008. Our overarching hypothesis is that medical therapy has improved to a degree that only certain subgroups of patients may benefit from revascularization and that for many patients medical therapy may be the preferred treatment strategy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Marijuana Use in Older Adults: Health, Function and Fall-Related Injury
-
批准号:10132223
-
项目类别:
-
资助金额:$59.78万
-
财政年份:2019
-
负责人:Salomeh Keyhani
-
依托单位:
Marijuana Use in Older Adults: Health, Function and Fall-Related Injury
-
批准号:10576324
-
项目类别:
-
资助金额:$56.27万
-
财政年份:2019
-
负责人:Salomeh Keyhani
-
依托单位:
Risks of Cannabis Use Among Veterans on Long-term Opioid Therapy
-
批准号:10312709
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:Salomeh Keyhani
-
依托单位:
Risks of Cannabis Use Among Veterans on Long-term Opioid Therapy
-
批准号:10817659
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:Salomeh Keyhani
-
依托单位:
Marijuana Use in Older Adults: Health, Function and Fall-Related Injury
-
批准号:10360509
-
项目类别:
-
资助金额:$57.81万
-
财政年份:2019
-
负责人:Salomeh Keyhani
-
依托单位:
Impact of marijuana on adherence, risk factor control and cardiovascular events
-
批准号:9404476
-
项目类别:
-
资助金额:$72.99万
-
财政年份:2017
-
负责人:Salomeh Keyhani
-
依托单位:
An Evaluation of Novel Domains for Predicting 30-Day Readmission
-
批准号:8576427
-
项目类别:
-
资助金额:$73.86万
-
财政年份:2013
-
负责人:Salomeh Keyhani
-
依托单位:
Comparative Effectiveness of Carotid Artery Revascularization vs Medical Therapy
-
批准号:8503392
-
项目类别:
-
资助金额:$77.06万
-
财政年份:2013
-
负责人:Salomeh Keyhani
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: